$BCRX Volume spike on Friday , lets hope history repeats
BCRX's berotralstat (BCX7353) is an orally active bradykinin inhibitor currently under review in Japan, the U.S., and Europe for the treatment of hereditary angioedema (HAE).
BCRX anticipates two regulatory approvals for berotralstat in 2020, and one early in 2021.
Even more impressive, however, is that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19.
First results from phase 3 studies of remdesivir in China in mild-moderate and severe COVID-19 are imminent. Results from similar studies in the U.S. should follow within a month.
BCRX will then likely experience even greater interest in its RNA replicase inhibitor, galidesivir. That is, remdesivir results will likely trigger a massive surge in BCRX stock price. Source seekignaplha
BCRX anticipates two regulatory approvals for berotralstat in 2020, and one early in 2021.
Even more impressive, however, is that BCRX will likely get a significant near-term boost from the success of GILD's remdesivir in the treatment of COVID-19.
First results from phase 3 studies of remdesivir in China in mild-moderate and severe COVID-19 are imminent. Results from similar studies in the U.S. should follow within a month.
BCRX will then likely experience even greater interest in its RNA replicase inhibitor, galidesivir. That is, remdesivir results will likely trigger a massive surge in BCRX stock price. Source seekignaplha